NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs
(Thomson Reuters ONE) -
EDINBURGH, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc
(Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on
significantly improving treatment outcomes for cancer patients by applying its
ProTide(TM) technology to transform some of the most widely prescribed
chemotherapy agents into more effective and safer medicines, announced today the
closing of its initial public offering of 7,596,505 American Depositary Shares
("ADSs") at a price to the public of $15.00 per ADS, which includes 929,505
shares sold upon partial exercise of the underwriters' option to purchase
additional ADSs, for total gross proceeds of approximately $114 million, before
deducting underwriting discounts and commissions. Each ADS represents one
ordinary share of NuCana. The ADSs began trading on the NASDAQ Global Select
Market on September 28, 2017 under the ticker symbol "NCNA." All ADSs were
offered by NuCana.
Citigroup, Jefferies and Cowen acted as joint book-running managers for the
offering, and William Blair acted as co-manager for the offering. A registration
statement on Form F-1 relating to these securities has been filed with the U.S.
Securities and Exchange Commission (the "SEC") and was declared effective on
September 27, 2017. Copies of the registration statement can be accessed by
visiting the SEC's website at www.sec.gov.
The offering was made only by means of a prospectus. Copies of the final
prospectus relating to the offering may be obtained by contacting Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146, Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by e-mail at
Prospectus_Department(at)Jefferies.com, or Cowen and Company, LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention
Prospectus Department or by phone at (631) 274-2806.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of such state or
jurisdiction.
For readers in the European Economic Area
In any EEA Member State that has implemented the Prospectus Directive (as
defined below), this communication is only addressed to and directed at
qualified investors in that Member State within the meaning of the Prospectus
Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and
amendments thereto, including Directive 2010/73/EU, to the extent implemented in
each relevant Member State), together with any relevant implementing measure in
the relevant Member State.
For readers in the United Kingdom
There will be no offer of ADSs to the public in the United Kingdom. This
communication, in so far as it constitutes an invitation or inducement to enter
into investment activity (within the meaning of section 21 of the Financial
Services and Markets Act 2000 as amended ("FSMA")) in connection with the
securities which are the subject of the offering described in this press release
or otherwise, is being directed only at (i) persons who are outside the United
Kingdom or (ii) persons who have professional experience in matters relating to
investments who fall within Article 19(5) ("Investment professionals") of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
"Order") or (iii) certain high value persons and entities who fall within
Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations
etc.") of the Order; or (iv) any other person to whom it may lawfully be
communicated (all such persons in (i) to (iv) together being referred to as
"relevant persons"). The ADSs are only available to, and any invitation, offer
or agreement to subscribe, purchase or otherwise acquire such ADSs will be
engaged in only with relevant persons. Any person who is not a relevant person
should not act or rely on this document or any of its contents. This
communication does not contain an offer or constitute any part of an offer to
the public within the meaning of ss. 85 and 102B of FSMA or otherwise.
About NuCana plc
NuCana is a clinical-stage biopharmaceutical company focused on significantly
improving treatment outcomes for cancer patients by applying its ProTide(TM)
technology to transform some of the most widely prescribed chemotherapy agents,
nucleoside analogs, into more effective and safer medicines. NuCana's most
advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities
derived from the nucleoside analogs gemcitabine and 5-fluorouracil,
respectively, two widely used chemotherapy agents. Acelarin® is currently being
evaluated in clinical studies across several solid tumor indications, including
ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a
Phase 1 study for the potential treatment of a wide range of advanced solid
tumor cancers.
For more information, please contact:
Hugh S. Griffith
Chief Executive Officer
NuCana plc
Tel: +44 131 248 3660
info(at)nucana.com
Westwicke Partners
Chris Brinzey
Tel: +1 339-970-2843
Chris.brinzey(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuCana plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2017 - 20:27 Uhr
Sprache: Deutsch
News-ID 562142
Anzahl Zeichen: 6639
contact information:
Town:
Edinburgh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 186 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs"
steht unter der journalistisch-redaktionellen Verantwortung von
NuCana plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
